Navigation Links
Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT

H. Lee Moffitt Cancer Center & Research Institute, working in partnership with the University of South Florida (USF), has discovered a new use for an old, previously discredited anti-cancer drug that could add another weapon in the arsenal against several cancers, including tumors of the breast, ovary, colon, skin and prostate.

The compound, tricirbine, was tested at various cancer centers from 1982 to 1996 and found to inhibit some cancers, but researchers failed to determine why. The Moffitt-USF team discovered that tricirbine works only against tumors in which the cancer-causing Akt protein is abundant and/or abnormally active.

"These tumors are addicted to hyperactive Akt and cannot survive without it," explains Saïd Sebti, Ph.D., Moffitt's Manuel and Adeline Garcia Professor, Leader of the Drug Discovery Program and Associate Director of Moffitt Research Institute. "What we discovered is a tailored therapy for tumors with a specific molecular signature."

Resurrecting tricirbine may be promising for patients with ovarian cancer, for instance, because "40 percent of women with ovarian cancer have tumors with high levels of active Akt," according to Sebti.

"To our knowledge, this is the first Akt inhibitor headed toward clinical trials," said Jin Cheng, MD, PhD, USF Professor of Pathology and Interdisciplinary Oncology.

Cheng and Sebti's study results were published in the journal Cancer Research.

VioQuest Pharmaceuticals Inc. (VQPH) of New Jersey is acquiring the licensing rights to the compound from USF through its merger with Greenwich Therapeutics Inc. and is planning clinical trials with Moffitt. The trials are expected to start within six to eight months. Patients will be selected for the trials based on whether their tumors have hyperactive Akt, which can be determined by a simple slide-stain test of tumor tissue.

Because tricirbine has previously been investigated in humans, the hypothesis-driven c linical trials planned at Moffitt can move directly into a PhaseI/II trial.

With the step-up of functional-genomics research at Moffitt and around the country, the advent of "customized medicine" has been heralded in headlines and at medical conferences. The clinical trial of this Akt-inhibitor is a concrete step toward that reality. Sebti says, "The beauty of this trial is that it's molecular therapy, based on the blueprint of the tumor cell."


'"/>

Source:University of South Florida Health Sciences Center


Related biology news :

1. Unchecked DNA replication drives earliest steps toward cancer
2. Virologists make major step towards understanding the process of HIV infection
3. Cats indifference towards sugar explained
4. A step toward the $1,000 personal genome using readily available lab equipment
5. A new step towards an AIDS vaccine
6. New GM mosquito sexing technique is step towards malaria control, report scientists
7. Novel method reveals how menthol discovery could point towards new or improved pain therapies
8. Scientists make first step towards holy grail of crystallography
9. Salk researchers make fast strides towards understanding how our body controls walking
10. Illegal trade is propelling rare turtle toward extinction, new report
11. Iraqs marshes show progress toward recovery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... Diego, Calif. (PRWEB) , ... May 25, 2016 , ... ... Diego area and has consistently been rated one of its top attractions. Fortune ... the globe to participate in a unique and intimate team-building experience. , Each event ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... Michael Fitzmaurice recently became double board-certified in surgery and surgery of the hand ... Dr. Fitzmaurice is no stranger to going above and beyond in his pursuit ...
(Date:5/25/2016)... LAKE CITY, UTAH. (PRWEB) , ... May 25, 2016 , ... ... efficiencies in healthcare information exchange, today announced that Charles W. Stellar has been named ... as WEDI’s interim CEO since January 2016. As an executive leader with more than ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... attacks, diabetes, and traumatic injuries, will be accelerated by research at Worcester Polytechnic ... into engines of wound healing and tissue regeneration. , The novel method, developed ...
Breaking Biology Technology: